Duan Xu-Hua, Wang Yan-Li, Han Xin-Wei, Ren Jian-Zhuang, Li Teng-Fei, Zhang Jian-Hao, Zhang Kai, Chen Peng-Fei
Department of Interventional Radiology, The First Affiliated Hospital, Zhengzhou University, No. 1, East Jian She Road, Zhengzhou, 450052, Henan Province, People's Republic of China.
PLoS One. 2015 Aug 5;10(8):e0134857. doi: 10.1371/journal.pone.0134857. eCollection 2015.
To determine the safety and feasibility of intraductal radiofrequency ablation (RFA) followed by locoregional tumor treatments in patients with non-resectable malignant biliary obstruction and stent re-occlusion.
Fourteen patients with malignant biliary obstruction and blocked metal stents were studied retrospectively. All had intraductal RFA followed by locoregional tumor treatments and were monitored clinically and radiologically. The practicality, safety, postoperative complications, jaundice remission, stent patency and survival time were analyzed.
Combination treatment was successful for all patients. There were no severe complications during RFA or local treatments. All patients had stent patency restored, with a decline in serum bilirubin. Three patients had recurrent jaundice by 195, 237 and 357 days; two patients underwent repeat intraductal RFA; and one required an internal-external biliary drain. The average stent patency time was 234 days (range 187-544 days). With a median follow-up of 384 days (range 187-544 days), six patients were alive, while eight had died. There was no mortality at 30 days. The 3, 6, 12 and 18 month survival rates were 100%, 100%, 64.3% and 42.9%, respectively.
Intraductal RFA followed by locoregional tumor treatments for occluded metal stents is safe and practically feasible and potential increase stent patency and survival times.
确定在不可切除的恶性胆管梗阻和支架再闭塞患者中,导管内射频消融(RFA)联合局部肿瘤治疗的安全性和可行性。
回顾性研究14例恶性胆管梗阻且金属支架堵塞的患者。所有患者均接受导管内RFA联合局部肿瘤治疗,并进行临床和影像学监测。分析其实用性、安全性、术后并发症、黄疸缓解情况、支架通畅情况及生存时间。
联合治疗对所有患者均成功。RFA或局部治疗期间无严重并发症。所有患者支架恢复通畅,血清胆红素下降。3例患者分别在195、237和357天出现复发性黄疸;2例患者接受了重复导管内RFA;1例需要内外胆管引流。平均支架通畅时间为234天(范围187 - 544天)。中位随访384天(范围187 - 544天),6例患者存活,8例死亡。30天无死亡病例。3、6、12和18个月生存率分别为100%、100%、64.3%和42.9%。
对于闭塞的金属支架,导管内RFA联合局部肿瘤治疗安全且切实可行,可能增加支架通畅时间和生存时间。